Abstract: Cells which make rhamnolipids and are genetically modified such that they have a decreased activity, compared to the wild type thereof, are provided. A glucose dehydrogenase and a method for producing rhamnolipids using the cells according to the invention are also provided.

Abstract: A polynucleotide, encoding an amino acid sequence, encoding an oxidoreductase, that is ?50% identical to an amino acid sequence of SEQ ID NO:1 (Geobacillus sp. PA9), SEQ ID NO:3 (Thermus thermophilus), SEQ ID NO:4 (Streptomyces globisporus), SEQ ID NO:5 (Clostridium aminobutyricum), SEQ ID:6 (Burkholderai cepacia), SEQ ID NO:8 (Oscillatoria sp. PCC 6506), or SEQ ID NO:9 (Paraburkholderia phymatum). The polynucleotide has an amino acid exchange in one or more of positions 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214 of SEQ ID NO:1, or at a corresponding position of the amino acid sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID:5, SEQ ID NO:6, SEQ ID NO:8, or SEQ ID NO:9.

Abstract: The invention relates to cells which make rhamnolipids and are genetically modified such that they have a decreased activity, compared to the wild type thereof, of a glucose dehydrogenase and to a method for producing rhamnolipids using the cells according to the invention.

Abstract: The present invention relates to at least one cell for producing at least one lipid with general formula II from at least one carbon substrate, wherein R1 and R2 independently of one another comprises identical or different organic radicals each with 5 to 13 carbon atoms, wherein the cell is a non-pathogenic cell that is genetically modified to increase the heterologous expression relative to the wild type cell of: an enzyme (E2) capable of converting 3-hydroxyalkanoyl-3-hydroxyalkanoyl-CoA/ACP or 3-(3-hydroxyalkanoyloxy)alkanoic acid (HAA) and NDP-glucose into ?-D-glucopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate.

Abstract: The invention relates to a mixture composition comprising glucolipids, to its use for producing formulations and to formulations comprising this mixture composition.

Abstract: The present invention relates to a compound of general formula I The present invention also relates to a method of producing N-acetyl homoserine and/or derivatives thereof, the method comprising contacting at least one recombinant cell in an aqueous medium with acetate wherein the recombinant cell comprises an increased activity relative to a wild type cell of (a) an enzyme E1, a homoserine dehydrogenase (EC1.1.1.3) and/or an enzyme E5, an aspartokinase (EC2.7.2.4); and (b) an enzyme E2, a homoserine O-acetyl transferase (EC2.3.1.31) and the acetate is maintained at a concentration of at least about 0.001 g/L in the aqueous medium.

Abstract: There is provided a microbial cell expressing a mutant AlkB enzyme, the mutant AlkB enzyme comprising at least one point mutation in the wild type sequence of AlkB, wherein the point mutation is at amino acid position V129 and/or T136 of the wild type AlkB enzyme. There is also provided a method for producing omega-hydroxy carboxylic acid and/or ester thereof using this cell.

Abstract: A microbial cell, which is genetically modified to increase the expression relative to the corresponding genetically unmodified cell of an AlkB alkane hydroxylase (Eb) having an amino acid sequence at least 95% identical with the amino acid sequence of SEQ ID NO: 1 and a wax-ester synthase (Ef) having an amino acid sequence at least 95% identical with the amino acid sequence of SEQ ID NO: 2. The cell does not have a genetic modification that increases formation of a carboxylic acid or a carboxylate ester from a simple carbon source.

Abstract: The present invention relates to at least one cell for producing at least one lipid with general formula II from at least one carbon substrate, wherein R1 and R2 independently of one another comprises identical or different organic radicals each with 5 to 13 carbon atoms, wherein the cell is a non-pathogenic cell that is genetically modified to increase the heterologous expression relative to the wild type cell of: an enzyme (E2) capable of converting 3-hydroxyalkanoyl-3-hydroxyalkanoyl-CoA/ACP or 3-(3-hydroxyalkanoyloxy)alkanoic acid (HAA) and NDP-glucose into ?-D-glucopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate.

Abstract: The invention provides a process for reacting a carboxylic acid ester of the formula (I) R1-A-COOR2??(I), wherein R1 is hydrogen, —CH2OH, —CHO, —COOR3, —CH2SH, —CH2OR3 or —CH2NH2, R2 is an alkyl group, R3 is hydrogen or an alkyl group, and A is a substituted, unsubstituted, linear, branched and/or cyclic alkylene, alkenylene, arylene or aralkylene radical having at least 4 carbons, in the presence of a cell. The process comprises a) contacting the cell with said carboxylic acid ester in an aqueous solution, wherein the cell is a recombinant cell which has reduced activity of a polypeptide comprising SEQ ID NO: 2 or a variant thereof over the wild-type cell.

Abstract: The present invention relates to a microbial cell for producing at least one L-amino acid from at least one C1-C4 alkane, wherein the cell comprises: (i) an increased expression relative to the wild type cell of Enzyme E1 capable of converting the alkane to a corresponding 1-alkanol; (ii) an increased expression relative to the wild type cell of Enzyme E2 capable of converting the 1-alkanol of (i) to a corresponding aldehyde; and either (iii) (A) an increased expression relative to the wild type cell of Enzyme E3 capable of converting the aldehyde of (ii) to a corresponding alkanoic acid; and a wild-type level expression of Enzyme E4 or an increased expression relative to the wild type cell of Enzyme E4 capable of converting the alkanoic acid of (iii) to a corresponding fatty acyl thioester; or ?(B) an increased expression relative to the wild type cell of Enzyme E5 capable of converting the aldehyde of (ii) to a corresponding fatty acyl thioester; ?and (iv) an increased expression relative to the wi

Abstract: A microbial cell is used for producing at least one fatty acid ester, wherein the cell is genetically modified to contain (i) at least one first genetic mutation that enables the cell to produce at least one fatty acid and/or acyl coenzyme A (CoA) thereof by increased enzymatic activity in the cell relative to the wild type cell of malonyl-CoA dependent and malonyl-ACP independent fatty acyl-CoA metabolic pathway, wherein the fatty acid contains at least 5 carbon atoms; and (ii) a second genetic mutation that increases the activity of at least one wax ester synthase in the cell relative to the wild type cell and the wax ester synthase has sequence identity of at least 50% to a polypeptide of SEQ ID NO: 1-8 and combinations thereof or to a functional fragment of any of the polypeptides for catalyzing the conversion of fatty acid and/or acyl coenzyme A thereof to the fatty acid ester.

Abstract: The invention relates to cells which make rhamnolipids and are genetically modified such that they have a decreased activity, compared to the wild type thereof, of a glucose dehydrogenase and to a method for producing rhamnolipids using the cells according to the invention.

Abstract: The present invention relates to a compound of general formula I The present invention also relates to a method of producing N-acetyl homoserine and/or derivatives thereof, the method comprising contacting at least one recombinant cell in an aqueous medium with acetate wherein the recombinant cell comprises an increased activity relative to a wild type cell of (a) an enzyme E1, a homoserine dehydrogenase (EC1.1.1.3) and/or an enzyme E5, an aspartokinase (EC2.7.2.4); and (b) an enzyme E2, a homoserine O-acetyl transferase (EC2.3.1.31) and the acetate is maintained at a concentration of at least about 0.001 g/L in the aqueous medium.

Abstract: The invention relates to cells which make rhamnolipids and are genetically modified such that they have a decreased activity, compared to the wild type thereof, of an ABC glucose transporter and, compared to the wild type thereof, an increased activity of at least one non-ABC glucose transporter and to a method for producing rhamnolipids using the cells according to the invention.

Abstract: There is provided a microbial cell expressing a mutant AlkB enzyme, the mutant AlkB enzyme comprising at least one point mutation in the wild type sequence of AlkB, wherein the point mutation is at amino acid position V129 and/or T136 of the wild type AlkB enzyme. There is also provided a method for producing omega-hydroxy carboxylic acid and/or ester thereof using this cell.

Abstract: The invention relates to a mixture composition comprising rhamnolipids, to a process for its preparation, to its use for producing formulations and to formulations comprising this mixture composition.

Abstract: The present invention relates to a method of preparing at least one rhamnolipid comprising: contacting a recombinant cell with a medium containing a carbon source; and culturing the cell under suitable conditions for preparation of the rhamnolipid from the carbon source by the cell, wherein the recombinant cell has been genetically modified such that, compared to the wild-type of the cell, the cell has an increased activity of at least one of the enzymes E1, E2 and E3, wherein the enzyme E1 is an ?/? hydrolase, the enzyme E2 is a rhamnosyltransferase I and the enzyme E3 is a rhamnosyl-transferase II, and wherein the carbon source is a C4 molecule.

Abstract: The invention relates to a cell which has been genetically modified so as to be capable of producing more 2-hydroxyisobutyric acid or more polyhydroxyalkanoates containing 2-hydroxyisobutyric acid monomer units than its wild type, characterized in that 2-hydroxyisobutyric acid or polyhydroxyalkanoates containing 2-hydroxyisobutyric acid monomer units are produced via acetoacetyl-coenzyme A as intermediate and 3-hydroxybutyryl-coenzyme A as precursor.

Abstract: A microbial cell is used for producing at least one fatty acid ester, wherein the cell is genetically modified to contain (i) at least one first genetic mutation that enables the cell to produce at least one fatty acid and/or acyl coenzyme A (CoA) thereof by increased enzymatic activity in the cell relative to the wild type cell of malonyl-CoA dependent and malonyl-ACP independent fatty acyl-CoA metabolic pathway, wherein the fatty acid contains at least 5 carbon atoms; and (ii) a second genetic mutation that increases the activity of at least one wax ester synthase in the cell relative to the wild type cell and the wax ester synthase has sequence identity of at least 50% to a polypeptide of SEQ ID NO: 1-8 and combinations thereof or to a functional fragment of any of the polypeptides for catalyzing the conversion of fatty acid and/or acyl coenzyme A thereof to the fatty acid ester.